PipISB
CB1 inverse agonist (Kb 1.5 nM) evaluated as a PET radiotracer in monkeys in 2009.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₂₇H₂₆FN₃O₃S
CID 58975213
- Family
- ECS pharmacological toolAntagonist or inverse agonist
- Molar mass
- 491.60 g/mol
Updated on
In plain terms
PipISB is not a medicine but a tracer: made radioactive, it can be used to visualise CB1 receptors in the living brain by positron emission tomography. In 2009, it was tested in monkeys, where it attached in regions rich in CB1 receptors. No use in humans was found in the sources consulted.
Receptors and activity
Target network
- Blocks or inhibits
- Binds or modulates
The lower the cited value, the closer the target sits to PipISB: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of PipISB.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1Inverse agonistno measured value cited
inverse agonist; functional antagonism constant Kb = 1.5 nM (value recalled in the introduction of Finnema et al. 2009, from earlier work)
- CB2Binding (function not established)no measured value cited
Kb greater than 7 000 nM (Finnema et al. 2009, same source): no useful affinity
Pharmacology
PipISB is an inverse agonist of the CB1 receptor designed as a radioligand: the aim is to measure, not to treat. Finnema and colleagues (2009) recall that it combines high potency (Kb of 1.5 nM at CB1) with high selectivity over CB2 (Kb above 7,000 nM), and that it can be labelled either with carbon-11, of short half-life, or with fluorine-18. In monkeys, brain uptake was highest in the striatum and cerebellum, reaching 170 to 270 % standardised uptake value (SUV) 120 minutes after injection of [11C]PipISB and 180 % 240 minutes after that of [18F]PipISB, with good retention in all CB1-rich regions; after pretreatment with a receptor-saturating dose of a CB1 ligand, values fell to 70-80 % SUV at 120 minutes for [11C]PipISB and to 25 % SUV at 240 minutes for [18F]PipISB. No reference region free of binding could be identified. The authors conclude that both radioligands show high CB1-specific binding in monkey brain in vivo and merit further investigation as PET radioligands in humans (Finnema et al. 2009). No human data were found in the sources consulted.
Key sources.
- Finnema et al., Synapse 2009: evaluation of [11C]PipISB and [18F]PipISB in the monkey as candidate radioligands for in vivo imaging of brain CB1 receptors (new tab)PMID 18925657
- PubChem, PipISB, CID 58975213 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
History
- Source
- Entirely synthetic compound with no known natural occurrence. It was prepared as a candidate radiotracer for positron emission tomography; no therapeutic use was found in the sources consulted.
Origin
Research tool
No known biosynthetic pathway: a synthetic molecule. It is an N-sulfonylated indole bearing a piperidine at position 3, linked through the sulfonyl group to an N-(4-fluorobenzyl)benzamide; carbon-11 is introduced on the amide carbonyl and fluorine-18 on the fluorobenzyl group (Finnema et al. 2009).
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. No marketing authorisation was found.
- France
Not classified: PipISB does not appear in the ANSM consolidated list of narcotics (updated 16/02/2026); on a literal reading, its structure (an N-sulfonylated indole with piperidine and benzamide) falls within none of the generic families of Annex IV (indol-3-yl methanones, indazol-3-yl methanones, naphthoylpyrroles, indole or indazole carboxylates and carboxamides, cyclohexylphenols, benzo[c]chromene nucleus). No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Antagonist or inverse agonist
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Finnema et al., Synapse 2009: evaluation of [11C]PipISB and [18F]PipISB in the monkey as candidate radioligands for in vivo imaging of brain CB1 receptors (new tab)PMID 18925657
- PubChem, PipISB, CID 58975213 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
Identifiers
Names
- IUPAC name
- N-[(4-fluorophenyl)methyl]-4-(3-piperidin-1-ylindol-1-yl)sulfonylbenzamide
- Other names
- [11C]PipISB · [18F]PipISB
Identifiers
- Formula
- C₂₇H₂₆FN₃O₃S
- PubChem CID
- 58975213(new tab)
- InChIKey
- RXTQWWFLLRSBCM-UHFFFAOYSA-N
- SMILES
- C1CCN(CC1)
C2= CN(C3= CC= CC= C32) S(= O) (= O) C4= CC= C(C= C4) C(= O) NCC5= CC= C(C= C5) F
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.